Alloy Therapeutics, Inc. is taking an unusual route to drug discovery and development, as it works to make open-source antibody discovery technology and related services more widely available. The company, which unveiled a $75m series C financing on 2 April, operates with a philosophy that biopharmaceutical companies should compete to create the best medicines rather than vie over access to the best technologies.
Based in Boston, the privately held firm previously raised about $17.5m total in its series A and B financings, CEO...






